Yuki Kita

8PUBLICATIONS
39CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 31, 2026
Oncological Outcomes and Prognostic Factors of Platinum-Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum-Based Chemotherapy Alone: A Propensity Score-Matched Analysis in a Real-World Population.

|Jul 02, 2026
Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

|Jul 18, 2025
Assessing Response Durability and Survival After Second-Line Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Validation of a Risk Model.

Samer Salah, Katsuhiro Ito, Yuki Kita

|Feb 11, 2025
Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma.

Toru Kanno, Katsuhiro Ito, Yuki Kita

|Feb 02, 2024
Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.

Yuki Kita, Hikari Otsuka, Katsuhiro Ito

|Dec 09, 2022
Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.

Katsuhiro Ito, Yuki Kita, Takashi Kobayashi

Pageof 2

Frequent Collaborators

8 joint publications

Takashi Kobayashi

6 joint publications

Katsuhiro Ito

2 joint publications

Kohei Hashimoto

2 joint publications

Takashi Kawahara